Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07252752

Dopamine and Insulin in Psychosis

Dopamine and Insulin in Psychosis: Imaging the Effects of Intranasal Insulin on Dopamine Transmission

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
46 (estimated)
Sponsor
Medical University of Vienna · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Patients with schizophrenia have a high risk of developing metabolic disorders and current evidence points to an overlap in mechanisms underlying psychiatric symptoms and metabolic disturbances. The main goal of this study is to investigate effects of brain insulin on dopamine signaling and energy metabolism in patients with schizophrenia experiencing their first psychotic episode (FEP). To this end, patients with schizophrenia and healthy volunteers will undergo two \[11C\]-(+)-PHNO positron emission (PET) scans to measure the changes in dopamine receptor availability after nasally applied insulin, as well as single proton magnetic resonance spectroscopy (1H-MRS) to assess the impact of intranasal insulin on levels of glucose and glutamate in the hippocampus.

Conditions

Interventions

TypeNameDescription
DRUGIntranasal Insulin160 IU intranasal insulin is administered using precision air pumps twice: 15 min prior to the PET scan and 35 min prior to the 1H-MRS scan
DRUGPlaceboInsulin-free dilution buffer is administered using precision air pumps 15 min prior to the PET scan
DRUGLow dose insulin infusion2.5 mU/kg insulin in 100 ml isotonic saline is infused intravenously over 15min prior to PET scan when placebo is administered intranasally
DRUGPlacebo infusion100 ml saline is infused intravenously over 15min prior to PET scan when insulin is administered intranasally
RADIATION[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)Each participant undergoes a 90-min \[11C\]-(+)-PHNO scan twice

Timeline

Start date
2026-01-01
Primary completion
2029-01-01
Completion
2029-01-01
First posted
2025-11-28
Last updated
2025-11-28

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT07252752. Inclusion in this directory is not an endorsement.